Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Metabolism of BMS-986231 in Healthy Males
NCT03210909Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cimlanod in heart failure (HF), sponsored by Bristol Myers Squibb. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Time of Last Quantifiable Concentration up to 8 days, Percent of Total Radioactivity Recovered in All Excreta up to 8 days and 4 more. Started Jun 2017; status: completed.
02
Drugs
cimlanod
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03210909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03210909.